Last reviewed · How we verify
TRAMETINIB
At a glance
| Generic name | TRAMETINIB |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2013 |
Approved indications
Common side effects
- Pyrexia
- Rash
- Headache
- Vomiting
- Musculoskeletal pain
- Fatigue
- Dry skin
- Diarrhea
- Nausea
- Epistaxis and other bleeding events
- Abdominal pain
- Dermatitis acneiform
Serious adverse events
- Decreased neutrophil count (Grade 3-4)
- Decreased LVEF
- Increased alanine aminotransferase (Grade 3-4)
- Increased aspartate aminotransferase (Grade 3-4)
Key clinical trials
- Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma (PHASE2)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) (PHASE2)
- Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (PHASE2)
- Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients (PHASE2)
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (PHASE1, PHASE2)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases (PHASE1)
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TRAMETINIB CI brief — competitive landscape report
- TRAMETINIB updates RSS · CI watch RSS